Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice.
Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice.
复制标题
C57BL/6 和 FVB/N 小鼠中吉非替尼诱导的皮肤不良反应 (SAR) 的比较。
DOI：
10.1093/toxres/tfab008
复制
发表时间：
2021
影响因子：
2.1
通讯作者：
Qian Hua
中科院分区：
文献类型：
--
作者：
Yali Zhang;Yalei Wang;Ziwei Chen;Shuo Cheng;C. Ding;Jiani Zhang;Tiantian Peng;Weihang Chen;Dingyang Zhang;Yan Tan;Xu Wang;Ruijuan Dong;Miao Jiang;Qian Hua
表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）如吉非替尼、厄洛替尼、阿法替尼等在临床上广泛应用，对晚期非小细胞肺癌的治疗效果显着。然而，服用EGFR-TKIs会出现一些不良反应，其中皮肤不良反应（SAR）是最常见的事件。目前SAR效果较差，SAR模型研究不足等问题亟待解决。本研究重点关注SAR模型，为机制研究奠定基础。吉非替尼 (Gefitinib) 是 EGFR-TKI 之一，被用作 SAR 诱导剂。我们选择C57BL/6和FVB/N小鼠作为实验模型，将其分为四组。每7天检测小鼠体重和皮肤水分，灌胃后第35天检测瘙痒行为和眼睑异常情况，并记录存活率。处死小鼠后评价单位面积毛发重量、胡须长度和炎症细胞。用吉非替尼治疗的C57BL/6动物在存活率、单位面积毛发重量、皮肤水分变化、皮肤干燥、瘙痒行为、胡须不规则生长、眼睑异常和炎症细胞方面表现出显着差异；与对照组相比，接受吉非替尼治疗的 FVB/N 动物仅在存活率、胡须不规则生长和眼睑异常方面分别表现出显着差异。本研究比较了C57BL/6和FVB/N小鼠吉非替尼诱导SAR的异同，说明不同患者在临床上可能表现出不同的症状，为研究EGFR-TKIs诱导SAR的机制提供实验依据。
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib, erlotinib, and afatinib, are widely used in clinical practice and remarkably effective in treatment of advanced non-small cell lung cancer. However, there are some adverse effects while taking EGFR-TKIs, among which skin adverse reactions (SAR) are the most common events. At present, the poor outcome of SAR and insufficient research on SAR models need to be addressed. In this study we focused on the SAR models to lay a foundation for mechanism researches. Gefitinib, one of the EGFR-TKIs, was used as SAR inducing agents. We chose C57BL/6 and FVB/N mice as experimental model and they were divided into four groups. The weight and skin moisture of mice were detected every 7 days, itching behavior and abnormal eyelids were tested at 35th day after gavage, and survival rate was also recorded. The weight of unit area hair, length of whiskers and inflammatory cells were evaluated after mice sacrificed. C57BL/6 animals treated with gefitinib showed significant differences in survival rate, weight of unit area hair, skin moisture changes, skin dryness, itching behavior, whisker irregular growth, abnormal eyelids, and inflammatory cells; FVB/N animals treated with gefitinib only showed significant differences in survival rate, whisker irregular growth and abnormal eyelids, compared with the control group, respectively. In this study, we compared the similarities and differences of gefitinib-induced SAR between C57BL/6 and FVB/N mice, which illustrated different patients probably showing different symptoms clinically and provided experimental basis for researching mechanism of EGFR-TKIs induced SAR.
影响因子：
17.1
作者：
Lichtenberger, Beate M.;Gerber, Peter A.;Sibilia, Maria
通讯作者：
Sibilia, Maria
影响因子：
45.3
作者：
Hidalgo, M;Siu, LL;Rowinsky, EK
通讯作者：
Rowinsky, EK